Topical Aganirsen Found To Be Active In Retinal Disease
Friday, May 11th, 2012Latest news:
Flow Clause Ratings:
Gene Indicate, a accompany focussed on development advanced drugs to supervise angiogenesis based weather, has proclaimed that overconfident information from a survey of aganirsen (GS-101, eye drops) in a nonhuman prelate simulation of choroidal neovascularization has been presented at the 2012 ARVO One-year Merging in Fortify Lauderdale, Florida. Topical governance of aganirsen was constitute to suppress neovascular maturation and escape in this exemplar and powerfully suggests a part for the dose campaigner in hum retinene neovascular diseases such as wet age-related macular decadence (AMD) and ischaemic retinopathy. Factor Signaling’s aganirsen is an antisense oligonucleotide that is expected to over a stage III test for the handling of imperfect neovascularisation in the cornea in 2012. Clinical studies in retinene diseases are docket to commence during the s quartern 2012.






